← Scoopfeeds — Intelligent news, curated.
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
business

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Bloomberg Markets · Jun 22, 2026, 2:12 PM · Also reported by 4 other sources

Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open Interest." (Source: Bloombe

Read full story on Bloomberg Markets → More top stories

Also covered by

Yahoo Finance Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics Yahoo Finance AbbVie acquires Apogee Therapeutics for $10.9 billion Yahoo Finance AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion Yahoo Finance AbbVie to acquire Apogee Therapeutics in $10.9B deal

More in business

Investing.com
Nektar Therapeutics chief R&D officer sells $336,211 in stock
Investing.com
Sr. VP Jackson Noel sells $67,406 of Consumer Portfolio Services stock
Investing.com
Anterix chief reg & comm officer sells $7.5m in company stock
Investing.com
US judge blocks subpoenas to Minnesota officials in DOJ immigration probe
Bloomberg Markets
Morgan Stanley's Gower: Fed Holding Rates Through '26
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop